Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016

November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (...

biosensors Biofreedom stent
News | Stents | November 07, 2016

November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high...

Bionics trial, Medinol, BioNIR stent, elastic polymer

Imaging of stent struts after expansion, showing the elastic polymer used on Medinol’s BioNIR stent does not crack or flake off, possibly leading to better patient outcomes. 

News | Stents | November 07, 2016

November 7, 2016 – The large multinational randomized BIONICS study found that a novel elastic polymer coated...

Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting | November 02, 2016

November 2, 2016 — Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing...

Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting | November 01, 2016

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...

News | Stents Drug Eluting | October 31, 2016

October 31, 2016 — Micell Technologies Inc. announced that it presented five-year clinical safety and efficacy...

EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD
Feature | Stents Drug Eluting | October 31, 2016

October 31, 2016 — A major international study has found that...

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab | September 28, 2016

September 28, 2016 — The Cardiovascular Research Foundation (CRF) included 11 late-breaking trials and 16 first...

Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016

August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L. Gore & Associates...

Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent
News | Stents Drug Eluting | June 03, 2016

June 3, 2016 — Biotronik announced results establishing non-inferiority of the Orsiro hybrid...

Biosensors' Biomatrix stent.

Feature | Stents | May 16, 2016

May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables...

Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting | April 21, 2016

April 21, 2016 — Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its...

Absorb, bioresorbable stents
Feature | Stents Bioresorbable | April 13, 2016 | Dave Fornell

Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings...

Biotronik, BIOSCIENCE trial, Orsiro hybrid DES, drug-eluting stent, STEMI heart attack patients
News | Stents Drug Eluting | March 07, 2016

March 7, 2016 — Biotronik announced publication of results from the...

Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting | February 02, 2016

February 2, 2016 — Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of...

Overlay Init